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Abstract. One challenge of squamous cell carcinoma of the 
head and neck (SCCHN) chemotherapy is a small percentage 
of tumor cells that arrest in the G0 phase of the cell cycle and 
are thus not affected by chemotherapy. This could be one reason 
for tumor recurrence at a later date. The recruitment of these 
G0-arresting cells into the active cell cycle and thus, prolif-
eration, may increase the efficacy of chemotherapeutic agents. 
The aim of this study was to investigate whether stimulation 
with recombinant epidermal growth factor (EGF) or serotonin 
leads to an increased tumor cell proliferation in xenografts. 
Detroit 562 cells were injected into NMRI-Foxn1nu mice. 
Treatment was performed with 15 µg murine or human EGF, or 
200 µg serotonin. The control mice were treated with Lactated 
Ringer's solution (5 mice/group). Tumor size was measured on 
days 4, 8 and 12 after tumor cell injection. The EGF stimulated 
mice showed a significantly higher tumor growth compared to 
the serotonin-stimulated mice and the untreated controls. In 
the present study, we show that it is possible to stimulate tumor 
cells in xenografts by EGF and thus, enhance cell proliferation, 
resulting in a higher tumor growth compared to the untreated 
control group. In our future investigations, we plan to include a 
higher number of mice, an adjustment of the EGF dosage and cell 
subanalysis, considering the heterogeneity of SCCHN tumors.
Introduction
Squamous cell carcinoma of the head and neck (SCCHN) is 
the 6th most common cancer type worldwide (1). The majority 
of cancers of the upper aerodigestive tract are of squamous 
cell origin (2). In Germany, >15,000 new cases of oral, pharyn-
geal and laryngeal carcinoma are reported each year (3). It is 
well-known that tobacco and alcohol consumption, as well as 
human papillomavirus (HPV) infection are associated with 
the development SCCHN.
The epidermal growth factor receptor (EGFR) is a basic 
cellular regulator of essential functions that regulate the 
survival, migration and proliferation of cells. EGFR signaling 
is impaired in various cancers. In SCCHN, EGFR is found to 
be overexpressed in 90% of cases (4). Its overexpression is an 
early event in SCCHN tumorgenesis and correlates with poor 
prognosis (4,5). Over the past decade, the knowledge of EGF 
overexpression in these tumors has led to the introduction 
of antibodies targeting EGFR for the treatment of head and 
neck cancer. For example, drugs such as the EGFR antibody, 
Cetuximab
© or the tyrosine kinase inhibitors, Gefitinib
© 
and Erlotinib
©, target EGFR and are often used in SCCHN 
therapy (6). The EGF ligand stimulates the proliferation of 
keratinocytes. Therefore, EGF promotes DNA synthesis and 
the progression from the G1 to the S phase of the cell cycle (7). 
Another mediator of the cell cycle is serotonin (5-HT). 5-HT is 
a growth factor, which regulates DNA synthesis. The mitogenic 
effect of 5-HT is thought to act via 5-HT1A and 5-HT1B (8).
In SCCHN therapy, platinum agents (cisplatin and 
carboplatin), taxanes (docetaxel) and antimetabolic agents 
(5-fluorouracil) are commonly used as chemotherapeutic 
drugs. These cytostatic drugs affect cells in the S or M phase. 
One challenge of SCCHN chemotherapy is that a small 
percentage of tumor cells do not proliferate (9). These cells 
arrest in the G0 phase of the cell cycle and are not affected by 
chemotherapy. This could be one reason for tumor recurrence 
at a later date. The recruitment of these G0-arresting cells into 
the active cell cycle and thus, proliferation, may increase the 
efficacy of chemotherapeutic agents.
Former in vitro experiments performed by Hambek et al 
(10), have provided evidence that the treatment of tumor cells 
with EGF and 5-HT can decrease the amount of dormant 
G0/G1 cells, resulting in more active, dividing cells that are 
consequently more sensitive to chemotherapeutic treatment. 
The aim of this study was to investigate whether tumor cell 
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stimulation with EGF and 5-HT can affect tumor growth in 
xenografts.
Materials and methods
Cell culture. Detroit 562 cells (CCL-138; American Type 
Culture Collection) were cultured in Eagle's minimum 
essential medium (10% FCS, 0.5 mM sodium pyrovate, 
25 mg gentamycin) at 37˚C and 5% CO2. For injection, cells 
were detached with Accutase (PAA Laboratories) and the 
concentration of living cells was determined using Cedex XS 
cell counter (Innovatis). The cells were diluted in Lactated 
Ringer's solution in a concentration of 5x10
6 cells/0.1 ml. The 
injection solution was transferred on ice to where the animals 
were housed.
Mice, tumor xenografts and treatment. Mice were housed in 
a pathogen-free facility for a 12-h light-dark cycle and with 
free access to food and water. Six-week-old female NMRI-
Foxn1nu mice (Harlan) were anesthetized with forane (Baxter) 
evaporated with Dräger Forena Vapor (19.3). Five million cells 
(100 µl) were subcutaneously (s.c.) injected into the flank of 
each mouse. One day after tumor cell injection, treatment was 
performed with 15 µg EGF (murine EGF; mEGF) (315-09; 
PeproTech), human EGF (hEGF) (100-009; RELIATech 
GmbH), or 200 µg serotonin (B21263; Alfa Aesar). The control 
mice were treated with Lactated Ringer's solution. Each treat-
ment group consisted of 5 mice. Mice were treated as described 
above, daily for a period of 10 days. The tumor size was 
measured on days 4, 8 and 12 after tumor cell injection using 
a digital caliper. The tumor volume was calculated with the 
following formula: V = π/6 x length x width
2. All mice were 
sacrificed by the 12th day after tumor cell transplantation or 
before the tumors ulcerated.
Staining. After sacrifice, tumors were etched. One tumor was 
directly frozen in liquid nitrogen and the second was fixed 
in Notoxhisto (Quartett) and embedded in paraffin. Ki67 
and EGFR staining was performed on the frozen sections. 
Immunohistological staining for CD31 was carried out on the 
paraffin-embedded sections. CD31 is a marker for lymphatic and 
blood vessels. Ki67 (rabbit, dilution 1/200) (Ki681C01; DCS), 
EGFR (rat, dilution 1/200) (ab231; Abcam) and CD31 (rat, dilu-
tion 1/20) (DIA-310; Dianova) primary antibodies were used for 
the staining procedure. Incubation was carried out for 1 h at room 
temperature. Afterwards, we proceeded with the DCS Detection 
Line system (AD050POL-K, PD000POL-R), according to the 
supplier's instruction. Staining was performed with DAB reagent 
(DC137C100). The Fuchsin Substrate-Chromogen system 
(K0625; Dako) and HistoGreen (E109; Linaris). Images were 
taken under a Zeiss Axioplan 2 with an AxioCam ICc1 camera. 
Statistical analysis was performed with BIAS for windows version 
9.12 using one-way ANOVA. The animal experiments were 
approved by Regierungspräsidium Darmstadt, Hessen F66/08.
Results
Increased volume in EGF-treated tumors. The daily injection 
regime of EGF led to an enhanced tumor volume in both groups 
of mEGF- and hEGF-injected mice (Fig. 1A). After 12 days, 
the mean tumor volume in the hEGF-treated mice reached 
325±63 mm
3, whereas in the control mice, the mean tumor 
volume was only 240±89 mm
3. The mean tumor volume in the 
mEGF-treated mice was 376±88 mm
3, which was comparable 
to that of the hEGF-treated mice (Fig. 1B).
In all tumors, the rate of intratumoral connective tissue was 
constant at 33-67% of the tumor tissue (±4%, data not shown) 
indicating that growth increase was caused by tumor prolifera-
tion and not by edema or an increase in connective tissue. The 
maximal growth increase was measured between days 4 and 8 
(Fig. 1C). During this time, hEGF-stimulated tumors grew 
by 267±46%, the tumors of the mEGF-treated mice grew by 
257±47% and the control tumors only increased by 185±38%; 
however, this did not reach statistical significance (p>0.05). 
The tumors of the 5-HT-treated mice showed a lower growth 
increase compared to the control tumors and reached a final 
volume of 155±54 mm
3 (Fig. 1A).
EGF treatment increases the risk of tumor ulceration. The 
experiment was terminated by the 12th day or when tumor 
ulceration occured. After this treatment period, 1 control 
tumor, 4 tumors from the hEGF-treated mice and 5 mEGF-
treated tumors had ulcerated (Fig. 2). This destruction of the 
surface epithelium is a common event in SCCHN patients 
(11) and also in xenograft models. We graded the ulceration 
process into 3 categories. At the beginning, the tissue beyond 
the tumor was unremarkable or showed a rose shading and 
was assigned to category 1 (cat. 1). Category 2 (cat. 2) was 
characterized by red marbling and violet spots under the skin. 
Finally, tumor ulceration occured [category 3 (cat. 3)]. In our 
experiment, the tumors of the EGF-treated mice ulcerated 
more frequently than those of the control group.
The amount of vessels in the intratumoral connective 
tissue remained equal in the control and hEGF-treated tumors 
(6±4%, data not shown) (sample images shown in Fig. 3). In the 
5-HT-treated mice, the tumor ulceration rate was comparable 
to that of the control mice. We did not observe any vessel inva-
sion in this group (Fig. 1D).
The majority of xenograft tumor cells express EGFR and Ki67. 
Detroit 562 cells overexpress EGFR (12). Immunohistological 
staining of EGFR indicated that high levels of EGFR were 
present in the cell cultures and tumor xenografts (Fig. 4). 
Almost all tumor cells expressed EGFR. In vitro-cultured 
Detroit 562 cells had an equal amount of EGFR in each cell. 
In the mouse xenografts, the level of EGFR expression varied 
in the cells. The EGFR expression seemed to depend on the 
localization of the cell. Tumor cells that were located next to 
the necrotic core of the tumor cell nests had lower quantities of 
EGFR. By contrast, most cells at the borders had a high EGFR 
expression. The reduction in EGFR was potentially caused by 
necrosis or tumor cell differentiation. In the skin, for instance, 
the amount of EGFR is reduced during the differentiation 
process (7).
Seventy-four percent of the in vitro-cultured Detroit 562 
cells were Ki67-positive (Fig. 4). In the tumor xenografts, the 
majority of tumor cells was also Ki67-positive. The results 
showed that these cells were in the active cell cycle. However, 
a number of Ki67-negative cells was localized in the middle 
of the tumor cell nests. These cells were supposed to be quies-ONCOLOGY REPORTS  28:  785-790,  2012 787
cent in the G0 phase. The size of cell nests correlated with the 
number of inner Ki-67-negative cells. In the EGF-stimulated 
mice, the number of Ki-67-positive cells was much higher.
The 5-HT-treated mice presented with several severe 
side-effects, such as depressed behavior, tremors, respiratory 
depression and sporadic diarrhea. The skins of the mice had 
also turned blue (Fig. 5A). Recovery from these side-effects 
was observed 1 h following treatment. Abdominal measure-
ment of body temperature documented a decrease in body 
temperature to 31˚C within 30 min (Fig. 5B). Two hours after 
injection, normal body temperature was measured. This was 
not observed in the EGF-stimulated mice.
Figure 1. Growth of tumor xenografts in hEGF-, mEGF-, 5-HT-treated mice and controls. (A) Tumor enlargement; (B) size of tumors on day 12; (C) growth 
increase of tumors in 4-day time intervals; (D) enlargement of ulcerating and non-ulcerating tumors; (E) amino acid sequence of hEGF and mEGF.
Figure 2. Ulceration of mouse tumors; cat. 1, unremarkable or slight shading; cat. 2, marbled stain and spots under the skin; cat. 3, ulcer. For details see 
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Discussion
Chemotherapeutic drugs affect cells in the S or M phase. 
One challenge of SCCHN chemotherapy is that a small 
percentage of tumor cells do not proliferate (9), and thus arrest 
in the G0 phase of the cell cycle. Therefore, these cells are not 
affected by chemotherapy. This could be one reason for tumor 
recurrence at a later date. The recruitment of these G0 cells 
Figure 4. Immunohistological staining of control and hEGF-treated mouse tumors, EGFR/CD31 and EGFR/Ki67 double staining, staining of Detroit 562-cul-
tured cells for Ki67 or EGFR. Quadratic area is enlarged, EGFR (brown), CD31 (green), Ki67 (red).
Figure 5. Physiological changes in 5-HT-treated mice. (A) Mouse 5 min after 5-HT injection; (B) body temperature of 5-HT-treated mice.
Figure 3. Immunohistological staining of control, hEGF-, mEGF- or 5-HT-treated mice for Ki67 and CD31. Arrows indicate vessel invasion.ONCOLOGY REPORTS  28:  785-790,  2012 789
into the active cell cycle and thus, proliferation, may increase 
the efficacy of chemotherapeutic agents.
In this study, we aimed to recruit non-cycling tumor cells 
into the mitotic cycle in order to sensitize them to chemo-
therapeutic agents. The majority of tumor cells express EGFR. 
They all have the potential to process the EGF signal. Our 
results showed that EGF stimulation enhanced tumor volume, 
indicating that the application of extra EGF had a proliferative 
effect on tumor cells. This effect did not differ in the hEGF- 
and mEGF-injected mice, a fact which could be explained 
with the homologous amino acid sequences. The increased 
tumor volume did not reach significance, when compared to 
the control tumors, a fact which could be caused by the small 
number of mice treated, the short treatment interval and the 
way of application or dosaging. The majority of resting cells 
was located in the center of the cell nests. Further studies are 
required in order to examine these cells in more detail. For 
tumor therapy, cells that can re-enter the cell cycle are the 
main focus of interest, as these cells can survive chemotherapy 
and lead to cancer recurrence. The arrest in the cell cycle 
may be caused by the large distance from the blood vessels. 
Consequently, chemotherapeutic agents cannot reach these 
cells. A treatment procedure containing various cycles of EGF 
and cytostatic drugs may potentially prove to be more effective.
EGFR is a multifunctional receptor involved in proliferation, 
motility, angiogenesis and survival of tumor cells (13). Three 
major pathways, PI3K/Akt, Ras/Raf/MEK/MAPK and PLC/
PKC, are involved in signal transduction (7). Further analysis 
will show which signaling cascade is activated. EGF-stimulated 
xenografts have a higher risk of ulceration. It is hypothesized 
that EGF application increases tumor cell invasiveness.
The amplitude of growth increase depends on the number 
of EGF receptors on the cell surface (14). Compared with A431, 
Detroit 562 tumors have a 3.6-fold lower EGFR-binding activity 
(12,14), which may result in lower growth induction compared 
to A431 xenografts.
Our results are consistent with the findings of Ozawa 
et al (14) and Ginsburg and Vonderhaar (15), which showed that 
EGF treatment stimulated the growth of SCCHN tumor xeno-
grafts, showing an increased tumor volume in the A431, NA and 
Ca9-22 cell line mouse xenografts after treatment with murine 
EGF. Factors such as gender-specific EGF host production (16), 
treatment interval, dosage and the way of application (osmotic 
pump or injection) affect the results. All EGFR ligands own 
the conserved EGF motive. It is characterized by 6 cysteines 
that form disulfide bridges with each other (17). The length 
of amino acid sequences between the cysteines of hEGF and 
mEGF is identical (CX7CX5CX10CXCX8C, X could be any 
amino acid). Furthermore, the recombinant EGFs have 70% 
sequence homology (Fig. 1E). The tumors of the 5-HT-treated 
mice showed a lower growth increase compared to the control 
tumors. Pratesi et al (18) described an increase in tumor growth 
after administration of 200 µg/day 5-HT delivered by osmotic 
mini-pumps in small lung cancer cell xenografts. 5-HT could 
have a dose-dependent effect, showing an inhibition of tumor 
growth when administered at lower doses (20 µg/day). One 
possible reason for tumor growth decrease could possibly be 
the reduction of blood flow in tumor vessels by 5-HT which 
impairs oxygen supply (19). 5-HT-treatment possibly does 
inhibit tumor growth via impact on tumor-feeding vessels. The 
decrease in tumor blood flow and, consequently, a deficit in 
oxygen and nutrient supply reduce the proliferation tempo (8). 
This effect would overcome the prospective pro-mitotic effect 
of 5-HT on tumor growth. 5-HT is not useful for our strategy 
to enhance proliferation. Our observations suggest vertical 
invasion of tumors. A possible active migration of tumor cells 
into the skin could destroy its structure. The administration of 
EGF may lead to an increased tumor cell motility. Seventy-four 
percent of the in vitro-cultured Detroit 562 cells were Ki67-
positive (Fig. 4). In tumor xenografts, the majority of tumor 
cells was also Ki67-positive. The results indicate that these 
cells are in the active cell cycle. A number of Ki67-negative 
cells was localized in the middle of the tumor cell nests. These 
cells were supposed to be quiescent. In the EGF-stimulated 
mice, the number of Ki-67 positive cells was much higher. The 
size of cell nests correlated with the number of inner Ki-67-
negative cells. It is possible that these resting cells are more 
differentiated. Another explanation could be that they do not 
have enough resources for mitosis. Oxygen diffuses into tissue 
and reaches a distance of approximately 100 µm. Due to the 
large distance to the feeding arterioles, these cells may stop 
cell cycling to prolong their survival (20). Most Ki67-positive 
cells also express high levels of EGFR. The Ki67-negative 
cells have reduced levels of EGFR.
In conclusion, in the present study we show that it is 
possible to stimulate tumor cells by EGF, and thus enhance 
cell proliferation, resulting in a higher tumor growth compared 
to the untreated control group. In our future investigations, we 
plan to include a higher number of mice and an adjustment 
of the EGF dosage, considering the heterogeneity of SCCHN 
tumors. Furthermore, we plan to treat EGF-stimulated SCCHN 
mice with chemotherapeutic drugs to investigate whether 
these mice show a better responce to therapy compared to a 
non-stimulated control group. These data may result in new 
clinical, stratified therapy regimes.
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